Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
Capital Increase in Genmab as a Result of Employee Warrant Exercise
03:26pm, Tuesday, 02'nd Mar 2021
Company Announcement
Transactions in connection with share buy-back program
04:03am, Monday, 01'st Mar 2021
Company Announcement
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
04:12pm, Friday, 26'th Feb 2021
Company Announcement
Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
04:08pm, Friday, 26'th Feb 2021
Company Announcement
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02:53pm, Thursday, 25'th Feb 2021
Company Announcement
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript
04:07pm, Tuesday, 23'rd Feb 2021
Genmab A/S (GMAB) CEO Jan van de Winkel on Q4 2020 Results - Earnings Call Transcript
Genmab announces initiation of share buy-back program
11:05am, Tuesday, 23'rd Feb 2021
Company Announcement
Company Announcement
Genmab, Seagen File US Application For Tisotumab Vedotin In Cervical Cancer Setting
05:36am, Thursday, 11'th Feb 2021
Genmab (NASDAQ: GMAB) and Seagen Inc (NASDAQ: SGEN) have jointly announced the submission of a marketing application with the FDA, seeking accelerated approval for tisotumab vedotin for the tre
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
04:05am, Saturday, 30'th Jan 2021
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private i
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
09:50am, Wednesday, 27'th Jan 2021
Company Announcement
Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
06:45am, Tuesday, 26'th Jan 2021
Company Announcement
Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference
10:16am, Wednesday, 06'th Jan 2021
Media Release Copenhagen, Denmark, January 6, 2021
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug
02:17pm, Tuesday, 05'th Jan 2021
Genmab (GMAB) starts the global phase III innovaTV 301 study evaluating tisotumab vedotin versus chemotherapy for treating recurrent/metastatic cervical cancer.
